Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: A review of 257 cases

Journal of Rehabilitation Medicine

Volumn 47, Issue 2, 2015, Pages 183-186

  Grosset, Donald G ^a   Tyrrell, Elaine G ^a   Grosset, Katherine A ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

AbobotulinumtoxinA; Blepharospasm; Botulinum toxins; Dystonia; Hemifacial spasm; IncobotulinumtoxinA; Torticollis; Type A

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; BLEPHAROSPASM; COST CONTROL; DRUG ADMINISTRATION; DYSTONIA; ECONOMICS; FEMALE; HEMIFACIAL SPASM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; TORTICOLLIS; TREATMENT OUTCOME;

ADULT; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; COST SAVINGS; DRUG ADMINISTRATION SCHEDULE; DYSTONIA; FEMALE; HEMIFACIAL SPASM; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NEUROMUSCULAR AGENTS; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84929145532     PISSN: 16501977     EISSN: 16512081     Source Type: Journal    
DOI: 10.2340/16501977-1895     Document Type: Article

References (15)

1. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013; 67: 94-114.
2. Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH, editors. Botulinum toxin: therapeutic clinical practice and science. Philadelphia, PA: Saunders Elsevier; 2009, p. 389-397.
3. Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011; 57: 555-565.
4. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-1018.
5. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64: 6-12.
6. Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm 2010; 117: 759-763.
7. Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005; 20: 937-944.
8. Rystedt A, Nyholm D, Naver H. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia. Clin Neuropharmacol 2012; 35: 278-282.
9. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs 2007; 67: 669-683.
10. Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008; 14: 407-414.
11. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16: 316-323.
12. Comella CL, Jankovic J, Truong D, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011; 308: 103-109.
13. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm - a randomized trial. Mov Disord 2011; 26: 1521-1528.
14. Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 2012; 22: 265-273.
15. Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IM, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol 2012; 259: 2519-2526.